IBRX
Price
$2.97
Change
-$0.08 (-2.62%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
2.53B
34 days until earnings call
PHAR
Price
$7.65
Change
-$0.67 (-8.05%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
547.81M
34 days until earnings call
Ad is loading...

IBRX vs PHAR

Header iconIBRX vs PHAR Comparison
Open Charts IBRX vs PHARBanner chart's image
ImmunityBio
Price$2.97
Change-$0.08 (-2.62%)
Volume$48.01K
Capitalization2.53B
Pharming Group
Price$7.65
Change-$0.67 (-8.05%)
Volume$200
Capitalization547.81M
IBRX vs PHAR Comparison Chart
Loading...
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IBRX vs. PHAR commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBRX is a Hold and PHAR is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (IBRX: $3.05 vs. PHAR: $8.32)
Brand notoriety: IBRX and PHAR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBRX: 86% vs. PHAR: 205%
Market capitalization -- IBRX: $2.53B vs. PHAR: $547.81M
IBRX [@Biotechnology] is valued at $2.53B. PHAR’s [@Biotechnology] market capitalization is $547.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBRX’s FA Score shows that 1 FA rating(s) are green whilePHAR’s FA Score has 1 green FA rating(s).

  • IBRX’s FA Score: 1 green, 4 red.
  • PHAR’s FA Score: 1 green, 4 red.
According to our system of comparison, both IBRX and PHAR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBRX’s TA Score shows that 4 TA indicator(s) are bullish while PHAR’s TA Score has 4 bullish TA indicator(s).

  • IBRX’s TA Score: 4 bullish, 5 bearish.
  • PHAR’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, PHAR is a better buy in the short-term than IBRX.

Price Growth

IBRX (@Biotechnology) experienced а +9.71% price change this week, while PHAR (@Biotechnology) price change was -5.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

IBRX is expected to report earnings on May 08, 2025.

PHAR is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IBRX($2.54B) has a higher market cap than PHAR($548M). IBRX YTD gains are higher at: 19.141 vs. PHAR (-23.994). PHAR has higher annual earnings (EBITDA): 7.56M vs. IBRX (-264.43M). PHAR has more cash in the bank: 172M vs. IBRX (150M). PHAR has less debt than IBRX: PHAR (127M) vs IBRX (504M). PHAR has higher revenues than IBRX: PHAR (286M) vs IBRX (14.7M).
IBRXPHARIBRX / PHAR
Capitalization2.54B548M463%
EBITDA-264.43M7.56M-3,500%
Gain YTD19.141-23.994-80%
P/E RatioN/AN/A-
Revenue14.7M286M5%
Total Cash150M172M87%
Total Debt504M127M397%
FUNDAMENTALS RATINGS
IBRX: Fundamental Ratings
IBRX
OUTLOOK RATING
1..100
68
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IBRXPHAR
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 16 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 16 days ago
62%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 16 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 16 days ago
65%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 16 days ago
82%
Advances
ODDS (%)
Bullish Trend 8 days ago
85%
Bullish Trend 21 days ago
67%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 23 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 16 days ago
71%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHAR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRFIX57.60N/A
N/A
MFS Research I
GDEUX21.37N/A
N/A
Goldman Sachs U.S. Equity ESG R6
LADTX25.00N/A
N/A
Lord Abbett Developing Growth R5
PJVQX22.57N/A
N/A
PGIM Jennison Value R6
TRDIX8.00N/A
N/A
Transamerica Sustainable Equity Inc I2

IBRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBRX
1D Price
Change %
IBRX100%
+3.04%
AXON - IBRX
48%
Loosely correlated
+3.18%
ARRY - IBRX
41%
Loosely correlated
+1.65%
CLRB - IBRX
38%
Loosely correlated
+3.46%
AMRN - IBRX
37%
Loosely correlated
-2.26%
VCYT - IBRX
35%
Loosely correlated
+1.93%
More

PHAR and

Correlation & Price change

A.I.dvisor tells us that PHAR and APLM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PHAR and APLM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAR
1D Price
Change %
PHAR100%
-8.11%
APLM - PHAR
31%
Poorly correlated
-16.13%
ADPT - PHAR
27%
Poorly correlated
-6.68%
IBRX - PHAR
27%
Poorly correlated
-2.62%
ATXS - PHAR
26%
Poorly correlated
-6.61%
SONN - PHAR
25%
Poorly correlated
-3.05%
More